TRPC proteins contribute to development of diabetic retinopathy and regulate glyoxalase 1 activity and methylglyoxal accumulation

Robin Sachdeva 1,2,9, Andrea Schlotterer 2,9, Dagmar Schumacher 1,9, Christin Matka 1,8, Ilka Mathar 1, Nadine Dietrich 2, Rebekka Medert 1, Ulrich Kribs 1, Jihong Lin 7, Peter Nawroth 4,5,6, Lutz Birnbaumer 7,8, Thomas Fleming 3,4, Hans-Peter Hammes 2, Marc Freichel 1,9

ABSTRACT

Objective: Diabetic retinopathy (DR) is induced by an accumulation of reactive metabolites such as ROS, RNS, and RCS species, which were reported to modulate the activity of cation channels of the TRPC family. In this study, we use Trpc1/4/5/6−/− compound knockout mice to analyze the contribution of these TRPC proteins to diabetic retinopathy.

Methods: We used Nanostring- and qPCR-based analysis to determine mRNA levels of TRPC channels in control and diabetic retinal cell types. Chronic hyperglycemia was induced by Streptozotocin (STZ) treatment. To assess the development of diabetic retinopathy, vaso-regression, pericyte loss, and thickness of individual retinal layers were analyzed. Plasma and cellular methylglyoxal (MG) levels, as well as Glyoxalase 1 (GLO1) enzyme activity and protein expression, were measured in WT and Trpc1/4/5/6−/− cells or tissues. MG-evoked toxicity in cells of both genotypes was compared by MTT assay.

Results: We find that Trpc1/4/5/6−/− mice are protected from hyperglycemia-evoked vasoregression determined by the formation of acellular capillaries and pericyte drop-out. In addition, Trpc1/4/5/6−/− mice are resistant to the STZ-induced reduction in retinal layer thickness. The RCS metabolite methylglyoxal, which represents a key mediator for the development of diabetic retinopathy, was significantly reduced in plasma and red blood cells (RBCs) of STZ-treated Trpc1/4/5/6−/− mice compared to controls. GLO1 is the major MG detoxifying enzyme, and its activity and protein expression were significantly elevated in Trpc1/4/5/6-deficient cells, which led to significantly increased resistance to MG toxicity. GLO1 activity was also increased in retinal extracts from Trpc1/4/5/6−/− mice. The TRPCs investigated here are expressed at different levels in endothelial and glial cells of the retina.

Conclusion: The protective phenotype in diabetic retinopathy observed in Trpc1/4/5/6−/− mice is suggestive of a predominant action of TRPCs in Müller cells and microglia because of their central position in the retention of a proper homoeostasis of the neurovascular unit.

1. INTRODUCTION

Reactive metabolites (RM), which accumulate under hyperglycemia, include reactive carbonyl (RCS), oxygen (ROS), and nitrogen (RNS) species, all of which contribute to the progression of diabetic long-term complications [1]. Such metabolites can impair the function of multiple cell types involved in diabetes-associated organ dysfunction leading to neuropathies and vasculopathies [1,2]. RM evoke post-translational modifications of numerous signaling molecules. Several types of cation channels have been identified as target molecules of such metabolites accumulating under hyperglycemia. The dicarbonyl methylglyoxal binds to Nα1.8 sodium channels to reduce inactivation and increase the excitability of nociceptive neurons [3]. Extracellular application of MG also activates TRPA1 channels by reversible binding to cysteine residues following permeation of the cell membrane. MG-mediated activation of TRPA1 leads to a rise in the intracellular concentration of numerous signaling molecules. Several types of cation channels have been identified as target molecules of such metabolites accumulating under hyperglycemia. The dicarbonyl methylglyoxal binds to Nα1.8 sodium channels to reduce inactivation and increase the excitability of nociceptive neurons [3]. Extracellular application of MG also activates TRPA1 channels by reversible binding to cysteine residues following permeation of the cell membrane. MG-mediated activation of TRPA1 leads to a rise in the intracellular concentration of numerous signaling molecules. Several types of cation channels have been identified as target molecules of such metabolites accumulating under hyperglycemia. The dicarbonyl methylglyoxal binds to Nα1.8 sodium channels to reduce inactivation and increase the excitability of nociceptive neurons [3]. Extracellular application of MG also activates TRPA1 channels by reversible binding to cysteine residues following permeation of the cell membrane. MG-mediated activation of TRPA1 leads to a rise in the intracellular

1Institute of Pharmacology, Heidelberg University, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany 2Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany 3Department of Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany 4German Center for Diabetes Research (DZD), Germany 5Institute for Diabetes and Cancer IDC Helmholtz Center Munich, Neuherberg, Germany 6Joint Heidelberg-IDC Translational Diabetes Program, Dept. of Medicine I, Heidelberg University Hospital, Heidelberg, Germany 7Neurobiology Laboratory, National Institute of Environmental Health Sciences, North Carolina, USA 8Institute for Biomedical Research (BIO MED), School of Medical sciences, Catholic University of Argentina, Buenos Aires, Argentina 9Contributed equally.

*Corresponding author. Fax: +49 6221 54 8644. E-mail: marc.freichel@pharma.uni-heidelberg.de (M. Freichel).

Abbreviations: DR, Diabetic Retinopathy; GLO1, Glyoxalase 1; GSH, Glutathione; GSSG, Glutathione disulfide; HTA, Hemithioacetal; MEF, Mouse Embryonic Fibroblast; MG, Methylglyoxal; NO, Nitric oxide; RCS, Reactive carbonyl species; RNS, Reactive nitrogen species; ROS, Reactive oxygen species; STZ, Streptozotocin; TRPC, Transient Receptor Potential Canonical

Received September 1, 2017 • Revision received December 18, 2017 • Accepted January 2, 2018 • Available online 5 January 2018

https://doi.org/10.1016/j.molmet.2018.01.003
To date, diabetic retinopathy is a prevalent complication, and is expected to be exacerbated in future decades due to diabetes, and the consequences of diabetes include microvascular complications. The APs from total brain and in hippocampus neurons using isoform heteromeric channels [8,9]. Recently, the formation of heteromeric channels by TRPC1, TRPC4, and TRPC5 was demonstrated using quantitative high-resolution mass spectrometry on affinity-purifications (APs) from total brain and in hippocampus neurons using isoform specific antibodies [10]. In the embryonic brain, TRPC1 and TRPC4 could also be co-immunoprecipitated with TRPC6 [11]. The cation channels formed by TRPC proteins are permeant for Ca$^{2+}$ and Na$^{+}$ under physiological conditions and are activated in response to activation of phospholipase C-coupled receptors but also by various reactive metabolites accumulating under diabetic conditions [12,13]. For TRPC5, it has been shown that nitric oxide (NO) donors lead to S-nitrosylation of cysteine residues in the channel pore, evoking an increased open probability of the channel [14]. TRPC5 channel activity was also increased by application of the reduced form of glutathione (GSSG) [16]. TRPC1 and TRPC4 modulate the sensitivity of TRPC5 channels towards RNS and ROS [14]. TRPC3, TRPC4, and TRPC6 were also found to be redox-sensitive channels, and their expression and activity were reported to be modulated by ROS species [17,19]. Numerous studies have investigated the differential regulation of members of the TRPC subfamily in experimental models of diabetes, including the streptozotocin (STZ) model, Zucker obese rat, Goto-Kakizaki rats, and db/db mice, as well as in human cells cultured under hyperglycemic conditions. However, depending on the study and the model system used, contradictory findings have been reported with respect to the transcription and expression of the TRPCs [19]. So far, the functional relevance of TRPC cation channels in diabetic complications was primarily analyzed at the cellular level, e.g. in cells contributing to microangiopathy and nephropathy such as cultured vascular smooth muscle cells, platelets or mesangial cells [19]. The relevance of TRPCs for diabetic complications has not been studied in complex disease models, in part, due to the lack of specific antagonists for individual TRPC channels, as well as the limitations of knock-down approaches for long-term studies in vivo.

To date, diabetic retinopathy is a prevalent complication, and is expected to increase in magnitude, given the global epidemic of type 2 diabetes, and the lack of a specific systemic treatment beyond glucose control. Treatments such as laser photocoagulation and intravitreal injections of anti-proliferative or anti-inflammatory agents aim at late disease stages, are invasive by nature, and have significant side effects. Diabetic retinopathy (DR) in rodents and humans affects almost all cell types and culminates in impaired function and structure from the point of inception. The initial vascular phenotype is avascularization, i.e. the loss of pericytes and endothelial cells. Neurodegeneration leading to a reduction of retinal thickness can occur as a consequence of progressive retinal capillary drop-out [20] but also as an independent process involving progressive cell death by apoptosis. In this process, accumulation of reactive metabolites and M6 can play an important role [20,21]. In this study, the causal contribution of four TRPC proteins, TRPC1, TRPC4, TRPC5, and TRPC6, was investigated with respect to their role in DR by comparing Trpc1/4/5/6$^{-/-}$ (TRPC QKO) mice to wild-type controls in the STZ-induced model of diabetes.

2. METHODS

2.1. Mice

To analyze the mRNA expression level of TRPCs by Nanostring, we used wild-type and Ins2$^{Ako}$a/b mice with C57BL/6J background as a model for type 1 diabetes [22]. The quadruple Trpc knockout mouse line Trpc1/4/5/6$^{-/-}$ was generated by intercrossing mice of the four mouse lines Trpc1$^{−/−}$ [23], Trpc4$^{−/−}$ [24], Trpc5$^{−/−}$ [25], and Trpc6$^{−/−}$ [26] mice. The Trpc1/4/5/6$^{-/-}$ mice had a mixed C57Bl6-129SvJ genetic background, and age and sex matched first generation (F1) offspring of C57Bl6/N and 129SvJ matings were used as controls. Trpc1/4/5/6$^{-/-}$ mice were routinely genotyped using primers specific for the corresponding Trpc-deficient alleles as described before [23–26]. Both mouse lines were bred and maintained at our university’s Specific Pathogen Free (SPF) central animal facility. We used 8–12 weeks old male mice and treated them with STZ (Sigma-Aldrich, Taufkirchen, Germany) as described previously [3]. Briefly, mice received one STZ injection/day i.p. (60 mg/kg) for five days, and blood glucose levels were maintained in the range of 300–500 mg/dl by insulin glargine treatment twice weekly according to blood glucose levels (Accu-Chek Aviva, Roche, Mannheim, Germany). Glycated hemoglobin (HbA$_{1c}$) was determined by cation-exchange chromatography on a PolyCAT A column [27]. Mice were kept in standard 12 h light/dark cycle and provided free access to standard chow diet and water. Markers for retinopathy, neurodegeneration, and methylglyoxal measurement were analyzed 30 weeks after the development of hyperglycemia. All animal experiments were conducted in accordance with the relevant guidelines by the EU Directive 2010/63/EU and approved by the local Animal Care and Use Committee at the regional authority in Karlsruhe, Germany.

2.2. Analysis of TRPC expression in retina

Total RNA was extracted from retinae of 8-month-old Ins2$^{Ako}$a/b mice and nondiabetic control mice using TRIZOL method (Thermo Fisher, Germany). RNA concentrations were measured using spectrophotometer (Infinity 200 PRO Nanoquant, TECAN, Austria) and microfluidic analysis (Bioanalyzer 2100, Agilent Technologies, USA). Analysis of the transcripts was done by NCounter Nanostring technology in a three-step method described by Geiss et al. [28]. Briefly, in the first step, two probes, the reporter and the capture probe, hybridize directly to the target molecule in solution. Then, the target—probe complexes are immobilized on the imaging surface of the nCounter Cartridge by binding to the capture probe. Finally, the sample cartridges are scanned by an automated fluorescence microscope, and molecular barcodes (fluorophores contained in the reporter probe) for each specific target are counted. For expression analysis by NCounter NanoString technology, 1 µg total RNA was hybridized (four biological replicates, RIN > 8.3) with a NanoString Gene Expression CodeSet and analyzed using the nCounter Digital Analyzer (NanoString Technologies, Seattle, USA). Background correction was performed, and normalization was applied using 5 different reference genes (Hprt1, Tbp, Ubc, Gapdh, Actb). Trpc specific DNA sequences used are listed in Supplementary Table 1.
2.3. Quantification of vasoregression and pericyte loss
Quantitative retinal morphometry was performed on retinal digest preparations to evaluate numbers of acellular capillaries (ACs/mm² retinal area) and pericytes (pericytes/mm² capillary area), according to published methods [29]. Briefly, after enucleation, eyes were fixed in 4% formalin for two days at room temperature. Retinas were isolated from the eyeball by opening it from the ora serrata. Isolated retinas were digested with 3% trypsin at 37 °C until the photoreceptor layer, and other retinal layers were digested, leaving behind the vasculature that can be seen under the low magnification microscope. To visualize the retinal morphology and morphometry, PAS staining was performed on the digested retinas. Microscopic quantification of acellular capillaries was done using the Cell-F software (Olympus opticals, Hamburg, Germany). Acellular capillaries were analyzed in ten randomly selected areas of the central retina (the area around the optic nerve). The total number of acellular capillaries was calculated to the total retina area. The total number of pericytes was analyzed in the ten randomly selected fields in the central retina under 400x magnification.

2.4. Expression analysis in cell lines and retinas using qPCR
RNA isolation was performed using the RNeasy Mini kit (Qiagen) according to manufacturer’s protocol for cells, including on-column DNase digest. For human Müller cells, cells were derived from one retina, for rat brain microglia from one Sprague Dawley rat, for Bovine Retinal Endothelial cells (BRECs) from 15 bovine retinae. cDNA synthesis was carried out using the SensiFAST cDNA synthesis kit (Bioline) according to manufacturer’s recommendations. Primers were designed with the online tool provided by Roche (https://lifescience.roche.com/en_de/brands/universal-probe-library.html) and the best primer pair for each target out of 2—3 was chosen from an initial qPCR screen. Quantitative expression analysis was performed using the Universal Probe system (Roche) with the corresponding FastStart cDNA synthesis kit (Bioline) and the best primer pair for each target out of 2—3 was chosen from an initial qPCR screen. Quantitative expression analysis was performed using the Universal Probe system (Roche) with the corresponding FastStart Essential DNA Probes Master (Roche) on a LightCycler 96 Instrument (Roche, Mannheim, Germany). Relative expression levels were obtained by normalizing to H3F3A, AIP and CXXC1 expression levels. Primer sequences can be found in the Supplementary Tables 2—4.

2.5. Retinal thickness and nuclei count
Analyses of thickness and number of cells in retinal nuclear layers were performed as described before [30]. Briefly, 3 μm thick Periodic Acid Schiff’s (PAS)- and hematoxylin-stained paraffin sections were used, and areas near the optic nerve were selected for measurements of the central retina using a microscope (Olympus, Hamburg, Germany) equipped with an analysis program (Olympus, Cell-F, Hamburg, Germany). The thickness of the entire retina and all retinal layers is expressed in μm. The number of cells in the ganglion cell layer was expressed per 250 μm of retinal length, the inner nuclear layer per 100 μm of retinal length and the outer nuclear layer per 50 μm of retinal length.

2.6. Methylglyoxal measurement in RBCs and plasma
The concentration of methylglyoxal in EDTA plasma and isolated RBCs was determined by derivatization with 1,2-diamino-4,5-dimethoxybenzene, according to the method described by McLellan [31].

2.7. Glyoxalase 1 activity
GL01 activity was determined spectrophotometrically as described previously [52]. Briefly, the initial rate of change in absorbance at 235 nm, caused by the formation of S-o-laactoylglutathione by GL01, is monitored. The assay mixture contained 2 mmol/L MG and 2 mmol/L GSH in sodium phosphate buffer (50 mmol/L, pH 6.6, 37 °C) and was incubated for 10 min to guarantee the complete formation of hemithioacetal (HTA). After the addition of the cytosolic protein fraction (5 μg/10 μL protein), the change in absorbance at 235 nm was monitored for 10 min. The activity of GL01 is expressed in units (U), where 1 U is the amount of GL01 which catalyzes the formation of 1 μmol/L of S-o-laactoylglutathione per minute.

2.8. Glyoxalase 1 protein expression
MEFs cytoplasmic extracts were used for GL01 protein expression analysis using western blot. Samples were loaded on a precast 4—12% gel (Invitrogen, Germany) and run at 80 V for 15 min and after that at 130 V for more than 1 h until the dye front reached the bottom of the gel. Samples were blotted onto a nitrocellulose membrane using Bis-Tris blotting buffer containing 20% methanol. Blotting was done at 9 V for 1 h. After blotting, the membrane was blocked with 5% milk powder in 1x TBS-T. Blocking was followed by brief washing with 1x TBS-T, and then, the membrane was incubated in the primary GL01 antibody (1:1000 diluted) (Abcam, UK) 12—15 h overnight. The next day, the membrane was washed briefly with 1x TBS-T and then incubated for more than 2 h with an anti-rabbit secondary antibody (1:50000 diluted) (GE Healthcare, UK). After washing briefly with 1x TBS-T, protein bands were detected by ECL chemiluminescence. Densitometric analysis was done to determine the intensity of immunostainings using Image J software. The signal intensity obtained by the anti-GL01 antibody was normalized to the signal intensity obtained by anti-z-Tubulin staining.

2.9. MTT assay
MEFs were seeded in 96 well-plates at a density of 25,000 cells per well and incubated overnight at 37 °C (5% CO2). The next day, cells were washed with PBS and then incubated with MG at the concentration indicated for 48 h. After that, 50 μL of MTT solution (2 mg/mL in H2O) was applied, and cells were incubated for 3 h. Subsequently, the medium was removed, and cells were lysed with 200 μL of DMSO. To dissolve the formazan crystals completely, the plate was incubated for another hour at room temperature, and then absorbance was measured at 590 nm with 620 nm as reference wavelength. Cell viability was calculated by normalizing the absorbance values for
Figure 2: Vasoregression and pericyte loss in diabetic retinas. (A) Representative images of PAS-stained retinal digest preparations. Acellular capillaries (AC) are marked with black arrows, scale bar represents 20 μm. (B) The number of pericytes per mm² of the capillary area was calculated from ten random selected fields of the circular area around the optic nerve. (C) The number of acellular capillaries per mm² of retina tissue was also analyzed in ten random selected fields of the circular area around the optic nerve. The number of animals analyzed for both acellular capillaries and pericyte loss was n = 5 in WT control, n = 6 in WT STZ-treated, n = 6 in Trpc1/4/5/6−/− mice (TRPC QKO) control, n = 5 in TRPC QKO STZ-treated. ***p < 0.001.
Figure 3: Analysis of central retinal thickness. (A) Representative images of retinal layers for all experimental groups, scale bar represents 50 μm. (B) Total retinal thickness and thickness of each retinal layer at the center were measured in diabetic WT and Trpc1/4/5/6−/− (TRPC QKO) mice and in the respective non-diabetic controls. ONL: Outer nuclear layer, INL: Inner nuclear layer, GCL: Ganglionic cell layer, OPL: Outer plexiform layer, IPL: Inner plexiform layer, PRL: Pigmented retinal layer. (n = 4 for WT and TRPC QKO diabetic and for the respective controls, *p < 0.05, **p < 0.01 and ***p < 0.001). (C) Analysis of number of nuclei in central retina in different retinal layers. A total number of nuclei in each retinal layer was counted in diabetic WT and TRPC QKO mice and also in their non-diabetic controls (n = 4 for WT and TRPC QKO diabetic and non-diabetic controls).
treated cells with the absorbance values of non-treated cells and expressed in percent.

2.10. Isolation of mouse embryonic fibroblast (MEF) cells
Primary mouse embryonic fibroblast (MEF) cells were isolated from E13.5 wild-type control and Trpc1/4/5/6/C0/C0 embryos, respectively, as described previously [24,33]. Cells were propagated in DMEM high glucose medium (Invitrogen, Germany) and used at passage 2 for enzyme activity, western blot, and MTT assay.

2.11. Statistical analysis
Results are shown as mean ± SD, unless stated otherwise. Statistical significance for Figures 2—4 and Supplementary Figure 1 was determined by two-way ANOVA (Tukey Test) whilst two-tailed unpaired Student’s t-test was used in all other figures. Differences with \( p < 0.05 \) were considered statistically significant. Significances are depicted as * \( p < 0.05 \), ** \( p < 0.01 \), and *** \( p < 0.001 \).

3. RESULTS

3.1. TRPC channels are abundantly expressed in retina
The expression pattern of Trpc genes in the retina under diabetic conditions was assessed using qPCR-based RNA analysis from citrate and STZ-treated wild type mice (Figure 1). Several TRPC channels were found to be abundantly expressed in the mouse retina. Transcripts of Trpc1, Trpc2 (a pseudogene in humans), Trpc3, and Trpc4 showed the highest relative expression, but Trpc5, Trpc6, and Trpc7 were also identified. In addition, we studied Trpc transcript abundance using a Nanostring-based RNA analysis in retinae of 32-week old control and Ins2Akita mice, which spontaneously develop diabetes due to a missense mutation in the insulin 2 gene. Also, here, most TRPC channels were found to be abundantly expressed. Specifically, Trpc1 mRNA was detected at very high levels, followed by Trpc3, Trpc4, and Trpc6 transcript levels in control as well as in the diabetic retinae. Expression of TRPC5 was also detectable. Notably, Trpc6 transcript levels were significantly higher in the retina of Ins2Akita mice compared to controls indicating an upregulation of TRPC6 transcripts under diabetic conditions (Supplementary Figure 2A).

3.2. Trpc1/4/5/6 quadruple knockout mice are protected from experimental diabetic retinopathy
To study the contribution of several TRPCs simultaneously in the diabetic condition, the Trpc compound knockout mouse line Trpc1/4/5/6/C0/C0 was used. In these mice, cation channels formed by TRPC1-, TRPC4-, TRPC5- and/or TRPC6 which are all subject to modulation by reactive metabolites have been inactivated. After 30 weeks of constant
hyperglycemia, mice were killed and retinopathy was assessed. In STZ-diabetic wild-type mice, we observed a marked decrease in the number of pericytes compared to non-diabetic controls. In contrast, diabetic Trpc1/4/5/6−/− mice were completely protected from pericycle loss (Figure 2B). Consecutively, the formation of acellular capillaries as a measure of both, pericyte and endothelial cell loss, was increased in hyperglycemic control mice compared to the normoglycemic condition (Figure 2A,C), but in diabetic Trpc1/4/5/6−/− mice, formation of acellular capillaries was completely absent (Figure 2A,C).

These results suggest that TRPC1−, TRPC4−, TRPC5−, and TRPC6-containing cation channels contribute to diabetic vasoregression.

3.3. Diabetes-evoked retinal neurodegeneration is reduced in Trpc1/4/5/6 quadruple knockout mice

We also aimed to analyze whether TRPC1/4/5/6 proteins play a role in neurodegeneration in the retina induced by the metabolic changes under chronic hyperglycemia. STZ-induced hyperglycemia reduced the overall retinal thickness, composed of the thickness of individual retinal layers measured in the center of the retina. Specifically, the outer nuclear layer (ONL), the inner nuclear layer (INL), the outer plexiform layer (OPL), the inner plexiform layer (IPL) and the pigmented layer (PRL) were reduced in thickness under diabetic conditions in wild-type mice. Only the ganglion cell layer (GCL) was unaffected by diabetes (Figure 3A,B). In contrast, there was no hyperglycemia-induced change in the thickness in any retinal cell layer in Trpc1/4/5/6−/− mice. The number of nuclei in the retina of both wild-type and Trpc1/4/5/6−/− mice was unchanged (Figure 3C).

3.4. TRPC channels are involved in the accumulation of reactive metabolites in tissues

To investigate the observed protection against the development of diabetic retinopathy in Trpc1/4/5/6−/− mice, we asked whether Trpc1/4/5/6−/− mice were exposed to a comparable glucose-dependent metabolic stress as wild-type controls, even though the HbA1c levels were not different between the two genotypes (Supplementary Figure 1A). An increase in the levels of the reactive metabolite methylglyoxal is known to mediate the development of diabetic retinopathy and was found in plasma samples of STZ-diabetic wild-type mice. However, in STZ-diabetic Trpc1/4/5/6−/− mice, the rise of MG plasma levels was significantly reduced compared to the STZ-treated wild-type group (Figure 4A). To examine whether the reduced extracellular accumulation of MG is also observed inside the cell, MG content in red blood cells (RBCs) was analyzed, and results show that the STZ-induced increase in MG levels in wild-type RBCs was again significantly reduced in Trpc1/4/5/6−/− mice to a similar extent as in the plasma (Figure 4B). These results suggest that TRPC channels are involved in the accumulation of the major hyperglycemia-related reactive metabolite MG.

3.5. Increased Glyoxalase 1 activity and protein expression enhances MG tolerance in Trpc1/4/5/6−/− cells

As GL01 is a key enzyme in the detoxification of MG, we measured GL01 enzyme activity in MEFs derived from Trpc1/4/5/6−/− mice. We detected a significant increase in GL01 activity in Trpc1/4/5/6−/− MEFs (Figure 5A), which was accompanied by an increased expression of the GL01 protein (Figure 5B). We hypothesized that Trpc1/4/5/6−/− cells are more resistant towards MG due to this increase in GL01 activity. To test this hypothesis, MTT-based viability assays were performed. We detected a right shift in the dose–response curve in Trpc1/4/5/6−/− MEFs (IC50 464 ± 108 μmol/L) as compared to wild-type controls (IC50 305 ± 31 μmol/L, Figure 5C). Accordingly, the percentage of viable Trpc1/4/5/6−/− MEFs was significantly higher compared to wild-type controls at a MG concentration of 500 μmol/L, indicating that they can tolerate detrimental MG levels better than the wild-type controls (Figure 5C, insert).

3.6. Increased Glyoxalase 1 activity in the retina may confer protection against development of diabetic retinopathy in Trpc1/4/5/6−/− mice

The increased GL01 activity detected in MEFs could be confirmed in vivo in the retina isolated from Trpc1/4/5/6−/− mice (Figure 6A,B). To analyze the expression of TRPC channels in cell types relevant to the development of DR, we measured mRNA levels in primary human Müller cells, in primary rat brain microglia and bovine retinal endothelial cells via quantitative real-time PCR (qPCR). Predominant and very high expression of TRPC1 compared to reference genes was observed in human Müller cells (Figure 6C) with Trpc4 and Trpc5 mRNAs also being detected. In rat microglia (Figure 6D), Trpc1 was also the major family member expressed in these cells, accompanied by low levels of Trpc6 mRNA. In bovine retinal ECs (Figure 6E), Trpc1, Trpc4, and Trpc5 transcripts were highly abundant and Trpc2, and Trpc6 mRNAs were present at low levels. Thus, Trpc1 is highly expressed in all cell types tested, and Trpc4 and Trpc5 are present in relevant amounts in Müller cells and retinal ECs.

4. DISCUSSION

In this study, we find that Trpc1/4/5/6−/− mice are protected from damage to the neurovascular unit and lack hyperglycemia-evoked vasoregression, a hallmark of DR, determined by the formation of acellular capillaries and pericyte drop-out. DR is accompanied by microangiopathic and neurodegenerative changes and cell death, which also leads to a reduction in overall thickness and thickness of the single retinal layers. However, the retinal layer thickness is unchanged by hyperglycemic conditions in Trpc1/4/5/6−/− mice in contrast to a marked reduction of layer thickness in hyperglycemic wild-types in all layers except the retinal ganglion cell layer. Diabetic complications such as retinopathy are mediated by an accumulation of reactive metabolites that include ROS, RNS, and RCS species. TRPC channel function can be modulated by such metabolites, but so far, a causative contribution of TRPC channels to diabetic complications has not been shown. Despite similar levels of hyperglycemia, Trpc1/4/5/6−/− mice showed reduced accumulation of the reactive metabolite methylglyoxal in plasma and RBCs. MG has been shown to contribute to the pathology of DR [21]. GL01 is considered as the major enzyme involved in the detoxification of MG, and we found an increase in GL01 enzyme activity in MEFs derived from Trpc1/4/5/6-deficient mice and in retina lysates from these mice. GL01 protein levels were also increased compared to wild-type mice. We found this increase in GL01 activity to be sufficient to mediate significant protection from MG-evoked cellular toxicity. These results indicate that TRPC channels containing any of the four TRPC1-C5/C6 proteins are involved in the regulation of GL01 activity, and loss of these channels leads to an increase in GL01 activity and MG detoxification which may confer protection from retinopathic changes in vivo. As we used TRPC-deficient mice with ubiquitous deletion of these proteins, our approach did not allow to differentiate in which retinal cell type(s) these channel proteins contribute to the development of retinopathy. However, we identified abundant expression of TRPC1, C4, and C5 in bovine retinal endothelial cells, which form heteromeric channels in other cells such as hippocampal neurons [10]. Additionally, we found TRPC1 to be predominantly expressed in rat brain microglial
MG-evoked cell toxicity in MEFs. MEFs were incubated with varying concentration of methylglyoxal (MG) and cell viability was determined using MTT assay. A bar graph shows the percentage of viable wild-type and Trpc1/4/5/6 QKO MEFs samples at the given MG concentrations. Three independent wild-type and Trpc1/4/5/6 QKO MEFs samples, respectively (**p < 0.01). The insert shows a bar graph of the mean values from the MTT assay for the three MEF preparations per genotype after treatment with 500 μM MG (**p < 0.01, error bars: SEM).

Figure 5: Increased Glyoxalase 1 activity and protein expression enhance MG tolerance in Trpc1/4/5/6−/− cells. (A) Cytoplasmic extracts of lysed mouse embryonic fibroblasts (MEFs) were used to determine glyoxalase 1 (GLO1) activity. The bar graph shows the averaged GLO1 activity from three independent wild-type and Trpc1/4/5/6−/− MEF preparations (**p < 0.05). (B) Upper panel: GLO1 protein expression in MEFs was analyzed in cytoplasmic extracts from MEF cells. Immunoblot with samples of 4 independent wild-type (WT1-WT4) and Trpc1/4/5/6−/− KO1-KO4 MEF preparations using anti-GLO1antibody are shown. α-tubulin was used as loading control. Lower panel: Densitometric quantitative analysis of the western blot shown above. The bar graph shows the average GLO1 to α-tubulin ratio of the 4 wild-type and Trpc QKO MEFs samples, respectively (**p < 0.01). (C) Large panel: Dose response curve for MG-evoked cell toxicity in MEFs. MEFs were incubated with varying concentration of MG for 48 h. The percentage of living cells was determined by MTT assay. Closed black squares represent the average of viable wild-type MEFs and the closed white circles the percentage of viable Trpc1/4/5/6−/− MEFs at the given MG concentrations. Three independent wild-type and Trpc1/4/5/6−/− MEF preparations were analyzed (**p < 0.01). The insert shows a bar graph of the mean values from the MTT assay for the three MEF preparations per genotype after treatment with 500 μM MG (**p < 0.01, error bars: SEM).
Figure 6: Increased Glyoxalase 1 activity in the retinas of Trpc1/4/5/6−/− mice. (A) The retinas were lysed by sonication, and cytoplasmic extracts were used to determine GLO1 activity and normalized to the total protein content in the cytoplasmic extracts. GLO1 activity for retinal extracts of five individual wild-type (WT1-5) and Trpc1/4/5/6−/− mice (KO1-5) is displayed (*p < 0.05). (B) Average GLO1 activity of the 5 wild-type and 5 Trpc1/4/5/6−/− retinae (*p < 0.05) displayed in (a). (C) Relative mRNA expression levels determined by quantitative real-time PCR (qPCR) analysis of Trpc transcripts in RNA samples derived from human Müller cells (n = 1). (D) Relative expression levels of Trpc transcripts in RNA samples determined in primary rat brain microglia cells (n = 1). (E) Relative expression levels of Trpc transcripts in RNA samples determined in bovine retinal endothelial cells (BRECs) (n = 15).
accumulation. TRPC5 activation was also shown to occur by interaction with oxidized glutathione (GSSG), which rises intracellularly upon MG accumulation [50]. GSSG was shown to activate TRPC5-containing channels via S-glutathionylation [16] and thus, Ca^{2+}-dependent cellular processes including cell death are triggered. Increased levels of the TRPC5 modulator GSSG can be evoked upon long-term exposure to MG [50,51]. MG accumulation under diabetic conditions leads to a decrease in endothelial cell number in vessels of mice with STZ-induced diabetes. Interestingly, EC death was prevented in mice overexpressing Glo1 [52], and GLO1 activity was shown to depend on TRPC channels in our study. In addition to the reactive metabolites mentioned before, a plethora of other agonists able to trigger TRPC channel activity could be envisaged under diabetic conditions as underlying mechanisms to initiate cellular processes and cell death in endothelial or other retinal cells. Despite various possible mechanisms discussed above, the identification of the exact trigger events underlying TRPC channel-mediated damage to the neurovascular unit will be subject for further investigations.

An emerging question for future studies will be to find the functional link between the presence of TRPC proteins and Glo1-mediated MG detoxification. Our data in TRPC deficient cells show an increase of Glo1 protein expression in MEF cells and in the retina homogenates, suggesting that TRPC function limits Glo1 protein expression and thereby Glo1 enzyme activity as well as MG detoxification. TRPC channels could mediate calcium-dependent gene expression via calcium-dependent transcription factors such as members of the NFAT family [53]. However, calcium-dependent suppression of genes would be rather an exception. Alternatively, TRPC function could modulate post-translational modification of Glo1 proteins. Recently, it was reported that a transient rise in cytosolic calcium levels results in more persistent ubiquitination of proteins [54,55]. If Glo1 proteins were also ubiquitylated in a Ca^{2+}-dependent manner, it would be conceivable that proteasome-targeting of the ubiquitinated Glo1 proteins and their degradation is reduced in TRPC-deficient cells. Finally, TRPC-mediating calcium entry could modulate Glo1 enzyme activity, but a variation of the calcium concentration across a wide range between 100 nmol/L to 3 μmol/L did not affect Glo1 enzyme activity in our experiments (data not shown). To corroborate that the increase in Glo1 expression and activity were responsible for the increased protection against MG in TRPC QKO cells, Glo1 antagonists could be used to see whether the improved viability in TRPC QKO MEF cells can be shifted to the range observed in WT cells. However, application of the Glo1 inhibitor S-p-bromoglutathione cyclopentyl diester (BBGC [56,57]) per se evoked considerable (>50%) cell death in MEF cells in concentrations needed for efficient enzyme inhibition (>5 μM, data not shown), hampering the significance of such an approach. Alternatively, the increase in Glo1 expression and enzyme activity does not necessarily denote whether Glo1-independent mechanism(s) also contribute to detoxification of MG or other reactive metabolites in the absence of TRPC1/4/5/6. Indeed, we have observed alternative pathways in cells, in which Glo1 expression and enzyme activity were abolished following Glo1 gene deletion in Schwann cells; here, we found up-regulation of genes encoding aldo-keto reductases (AKR) as well as an increase in AKR enzyme activity [58]. However, we found upregulation of AKR activity only when Glo1 was completely abolished, and the key enzymes of metabolic pathways that might be upregulated in TRPC QKO cells need to be identified as to causally address the relevance of such pathways.

Recently, an inhibitor of TRPC4- and TRPC5-homomorphic channels as well TRPC1/TRPC4- and TRPC1/TRPC5-heteromeric channels has been developed [59]. This blocker (compound C31 or picof145) has been shown to be highly potent (IC_{50} in the range of 5–1300 pm) and specific within the TRP channel family. However, its effectiveness in primary cells and in vivo has not yet been demonstrated. Apart from C31, there are other TRPC channel blockers available such as SAR7334 and ML204. SAR7334 blocks TRPC3, TRPC7, and, most potently, TRPC6 homomeric channels [60]. ML204 was identified as a TRPC4 and TRPC5 inhibitor. However, its pharmacokinetic properties limit its use in vivo [61]. SAR7334 application abolished hypoxia-induced increases in pulmonary arterial pressure in a similar way as observed in Trpc6−/− mice. Taken together, in this study, we demonstrate a causal contribution of TRPC proteins for the development of diabetic retinopathy in the murine STZ model and provide evidence that TRPC-mediated processes aggravating vasoregression as well as neurodegeneration in the retina may be due to a TRPC-mediated role in the accumulation of the reactive metabolite MG and its detoxification by Glo1. However, in future studies, the exact TRPC-containing channel entities and the cell type(s) that initiate(s) TRPC-dependent processes in DR need to be identified to understand the causative role of TRPCs in DR precisely.

**FUNDING**

This work was supported by several grants including SFB 1118 (“Reactive Metabolites as cause of diabetic long-term complications”) to MF, HPH, TF, PN, and the INTERNATIONAL RESEARCH TRAINING GROUP 1874/1 (Diabetic Microvascular Complications, DIAMICOM) and the Intramural Research Program of the NIH (project ZO!-ES-101684 to LB).

**CONFLICT OF INTEREST**

The authors confirm no conflict of interest associated with this manuscript.

**CONTRIBUTION STATEMENT**


**ACKNOWLEDGEMENT**

We thank Hans-Peter Gensheimer and Yoko Oguchi for technical assistance.

**APPENDIX A. SUPPLEMENTARY DATA**

Supplementary data related to this article can be found at https://doi.org/10.1016/j.molmet.2018.01.003.

**REFERENCES**


Original Article


